Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vical Incorporated has received Canadian Patent no. 2,365,416 and Japanese Patent no. 4,800,485 for its cationic lipid/co-lipid adjuvant - Vaxfectin.
Subscribe to our email newsletter
The patent includes composition of the Vaxfectin adjuvant, composition of Vaxfectin-formulated vaccines, and methods for their use.
Vical president and CEO Vijay Samant said Vaxfectin was discovered through extensive screening of Vical’s lipid portfolio, and represents the new class of adjuvants which can be used for both conventional and DNA vaccines.
"We have successfully demonstrated the adjuvant’s tolerability in three Phase 1 clinical trials with Vaxfectin-formulated vaccines against pandemic strains of influenza," Samant said.